News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trevi Therapeuitcs Presents Data at the 7th World Congress on Itch



9/25/2013 6:37:47 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Trevi Therapeutics, Inc. (“Trevi”), a clinical stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus, presented data on nalbuphine at the 7th World Congress on Itch.

Nalbuphine is a mixed mu antagonist/kappa agonist opioid. The effect of nalbuphine on substance P induced scratching was studied by Trevi in the mouse model. This model is relevant to antihistamine-resistant pruritus, which is observed in patients with various dermatopathologies.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES